tiprankstipranks
Trending News
More News >

Clover Biopharma Reports Loss Amid Cost Cuts

Clover Biopharma Reports Loss Amid Cost Cuts

Clover Biopharmaceuticals Ltd. (HK:2197) has released an update.

Don’t Miss TipRanks’ Half-Year Sale

Clover Biopharmaceuticals Ltd. reported a significant downturn, posting a loss of RMB 95.1 million for the first half of 2024, compared to a profit of RMB 650.6 million in the same period last year. This decline was attributed to non-recurring income from funding and a lack of inventory impairment provisions that bolstered the previous year’s results. Cost cuts in administration, sales, and R&D failed to offset the losses, with cash and bank balances also decreasing by RMB 265.7 million from the end of 2023.

For further insights into HK:2197 stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1